314 related articles for article (PubMed ID: 24975040)
1. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
3. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
[TBL] [Abstract][Full Text] [Related]
4. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
Wang L; Chen YZ; Shi D; Shi XY; Zou Z; Zhao JH
Drugs R D; 2011 Dec; 11(4):317-26. PubMed ID: 22133387
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Tamura K
Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
[TBL] [Abstract][Full Text] [Related]
9. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
10. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
11. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis.
Zhang D; Ye J; Xu T; Xiong B
J Chemother; 2013 Jun; 25(3):170-5. PubMed ID: 23783142
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
[TBL] [Abstract][Full Text] [Related]
13. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
15. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis.
Zhou F; Shao JH; Wu LQ; Yin XB; Yu X
Asian Pac J Cancer Prev; 2013; 14(4):2453-9. PubMed ID: 23725157
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
17. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
